Analysts Anticipate Certara, Inc. (NASDAQ:CERT) Will Announce Quarterly Sales of $79.78 Million

Brokerages expect Certara, Inc. (NASDAQ:CERTGet Rating) to announce sales of $79.78 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Certara’s earnings, with the lowest sales estimate coming in at $79.36 million and the highest estimate coming in at $80.20 million. Certara posted sales of $66.72 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 19.6%. The firm is scheduled to announce its next earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Certara will report full year sales of $355.51 million for the current financial year, with estimates ranging from $354.07 million to $357.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $409.37 million, with estimates ranging from $403.64 million to $419.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Certara.

Certara (NASDAQ:CERTGet Rating) last announced its earnings results on Tuesday, March 1st. The company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.08). The company had revenue of $75.35 million for the quarter, compared to analysts’ expectations of $83.26 million. Certara had a positive return on equity of 2.96% and a negative net margin of 4.64%. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period last year, the business earned ($0.37) EPS.

Several research analysts have recently commented on the stock. Barclays lowered their price objective on shares of Certara from $48.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, March 3rd. Jefferies Financial Group raised shares of Certara from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Tuesday, January 11th. Zacks Investment Research lowered shares of Certara from a “buy” rating to a “hold” rating in a research note on Tuesday, February 15th. Finally, Morgan Stanley lowered their price objective on shares of Certara from $27.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, March 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Certara presently has a consensus rating of “Buy” and an average target price of $31.00.

Shares of CERT stock opened at $18.35 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.98 and a quick ratio of 2.98. The firm has a market cap of $2.93 billion, a PE ratio of -229.35, a price-to-earnings-growth ratio of 0.72 and a beta of 1.69. The company has a 50-day moving average of $21.03 and a two-hundred day moving average of $27.26. Certara has a 1-year low of $17.70 and a 1-year high of $45.48.

In related news, Director Mason P. Slaine sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $26.61, for a total value of $1,330,500.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO William F. Feehery sold 90,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 17th. The shares were sold at an average price of $24.32, for a total transaction of $2,188,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 271,352 shares of company stock worth $6,175,266. 4.02% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors raised its holdings in Certara by 48.7% during the third quarter. Captrust Financial Advisors now owns 904 shares of the company’s stock worth $30,000 after purchasing an additional 296 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new stake in Certara during the fourth quarter worth approximately $32,000. American International Group Inc. raised its holdings in Certara by 127.3% during the third quarter. American International Group Inc. now owns 1,325 shares of the company’s stock worth $44,000 after purchasing an additional 742 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in Certara during the third quarter worth approximately $47,000. Finally, Hardy Reed LLC acquired a new stake in Certara during the first quarter worth approximately $89,000. 49.79% of the stock is currently owned by institutional investors.

Certara Company Profile (Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Read More

Get a free copy of the Zacks research report on Certara (CERT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.